Get started
Author

Kenji Tanabe

ORCID: 0000-0002-4122-5279
Observed ORCID: 0000-0002-4122-5279
OpenAlex ID: A5120979693
Time-Dependent Comparative Effectiveness of First-Line Treatment for Metastatic Clear Cell Renal Cell Carcinoma: A Restricted Mean Survival Time-Based Network Meta-analysis
2026 · Hiroshi Fukushima, Shugo Yajima, et al. · Targeted Oncology · 7
Re-evaluating Treatments for Advanced Urothelial Carcinoma Using Restricted Mean Survival Time: A Systematic Review and Network Meta-analysis
2026 · Shugo Yajima, Wei Chen, et al. · European Urology Open Science · 6
Clinical Features and Risk Factors of Enfortumab Vedotin–Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study ( YUSHIMA Study)
2025 · Takahiko Soma, Hajime Tanaka, et al. · International Journal of Urology · 6
PDF
Bayesian reanalysis of the NIAGARA trial using reconstructed individual patient data: perioperative durvalumab in cisplatin-eligible muscle-invasive bladder cancer
2026 · Kohei Hirose, Soichiro Yoshida, et al. · Japanese Journal of Clinical Oncology
Lymph node metastasis as a favorable prognostic factor in metastatic urothelial carcinoma with histological variants treated with pembrolizumab: a retrospective multicentric study (YUSHIMA study-04)
2026 · Ichiro Yonese, Fumitaka Koga, et al. · Japanese Journal of Clinical Oncology
PDF
Works count: 5
Citation count: 19
H-index: 3
I10-index:
Year
Topic
Type